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http:WHAT THIS PAPER ADDS
This study adds to growing evidence that exposure to secondhand smoke is not only a risk factor for cardio-
vascular disease, but also carries a disproportionately higher risk than active smoking for a given level of smoke
exposure. The main novelty of this study was the direct comparison, using several biomarkers, between non-
smokers with high levels of secondhand exposure, and light and moderate active smokers.Objective: Both active smoking and exposure to secondhand smoke (SHS) are associated with cardiovascular
disease, but sidestream smoke contains higher levels of small particles and toxic gases than mainstream smoke.
The relationship between the concentration of cotinine and a number of cardiovascular biomarkers among
nonsmokers and active smokers was examined.
Methods: A cross-sectional study using the Scottish Health Surveys conducted between 1998 and 2010 was
undertaken. Inclusion was restricted to participants aged 16 years who had provided saliva and blood samples.
Uni- and multivariate regression models were used to examine the relationships between the concentration of
cotinine and C-reactive protein (CRP), high-density lipoprotein (HDL) cholesterol, and ﬁbrinogen concentrations,
as well as total:HDL cholesterol ratios.
Results: Of the 10,018 eligible participants, 7,345 (73.3%) were conﬁrmed to be nonsmokers (cotinine <15.0 ng/
mL) and 2,673 (26.7%) were conﬁrmed to be current smokers (cotinine 15.0 ng/mL). CRP and total:HDL
cholesterol increased, and HDL cholesterol decreased, with increasing cotinine concentration across nonsmokers
and smokers (all p < .001). However, there were step changes at the interface, whereby nonsmokers with a high
exposure to SHS had lower concentrations of cotinine than light active smokers but comparable concentrations of
CRP (p ¼ .709), HDL cholesterol (p ¼ .931), and total:HDL cholesterol (p ¼ .405). Fibrinogen concentrations were
signiﬁcantly raised in moderate and heavy active smokers only (both p < .001).
Conclusion: Exposure to SHS is associated with disproportionately higher biomarkers of cardiovascular risk
compared with active smoking. Protection from exposure to SHS should be a public health priority.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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smoke exposureINTRODUCTION
Globally, cardiovascular disease (CVD) is the leading cause
of death and is projected to cause 23 million deaths per
annum by 2030.1 The global prevalence of smoking is
increasing, especially in large, developing countries such as
China. A 2013 World Health Organization report has indi-
cated that only 16% of the world’s population is covered by
comprehensive smoke-free legislations.2 Active smoking is
an established risk factor for coronary heart disease (CHD),rresponding author.
il address: jill.pell@glasgow.ac.uk (J.P. Pell).
-5884/$ e see front matter  2014 European Society for Vascular
. Published by Elsevier Ltd. All rights reserved.
//dx.doi.org/10.1016/j.ejvs.2014.09.008stroke, and peripheral arterial disease (PAD).3e5 There is
growing evidence that exposure to secondhand smoke
(SHS) is also a risk factor. Two meta-analyses reported
relative risks of 1.25 [95% conﬁdence interval (CI) 1.17e
1.32] and 1.25 (95% CI 1.12e1.38) for CHD and stroke,
respectively.6,7 To date, four cross-sectional studies have
examined the association with PAD,8e11 with three
reporting signiﬁcant associations.8,10,11 We previously
demonstrated that nonsmokers with cotinine concentra-
tions 2.7 ng/mL were signiﬁcantly more likely to have
intermittent claudication than those with cotinine concen-
trations <0.7 ng/mL (adjusted odds ratio 1.76, 95% CI
1.04e3.00).11
Active smoking is associated with higher concentrations
of cardiovascular biomarkers, including C-reactive protein
704 L. Lu et al.(CRP),12 ﬁbrinogen,13 and low-density lipoprotein (LDL)
cholesterol.14 SHS may contain both sidestream smoke,
from burning cigarette tips, as well as exhaled mainstream
smoke. Sidestream smoke contains higher concentrations of
small respirable particles (<2.5 mm) and toxic gases than
mainstream smoke inhaled by active smokers.15e18 Brief
exposure to SHS produces rapid changes in inﬂammatory
markers,19,20 resulting in concentrations comparable with
active smokers.21e23 Therefore, the sidestream smoke
inhaled by nonsmokers exposed to SHS may convey a
disproportionately higher risk of CVD. In the British Regional
Heart Study, the risk of CHD events over 20 years of follow-
up was comparable in nonsmokers exposed to high levels of
SHS [adjusted hazard ratio (HR) 1.57, 95% CI 1.08e2.28] and
light active smokers (adjusted HR 1.66, 95% CI 1.04e2.68) in
spite of cotinine concentrations being nearly 30-fold higher
in the latter group (mean 4.9 vs. 138 ng/mL).24
Scottish Health Surveys were used to explore the asso-
ciation between level of secondhand and active smoke
exposure, measured by salivary cotinine concentration and
a number of preclinical cardiovascular biomarkers [CRP,
high-density lipoprotein (HDL) cholesterol, total:HDL
cholesterol and ﬁbrinogen.METHODS
Data source
The Scottish Health Surveys are ongoing, repeated, cross-
sectional studies used to monitor the health and health-
related risk factors of the general population living in pri-
vate households across Scotland (http://www.scotland.gov.
uk/Topics/Statistics/Browse/Health/Scottish-health-survey).
The surveys were undertaken in 1995, 1998, and 2003, and
then annually from 2008 using a multistage, stratiﬁed
sampling frame. Each survey recruited different households.
The trained staff conducted face-to-face interviews and
obtained measurements, including height and weight. All
consenting individuals aged 16 years were visited by a
nurse and invited to provide a salivary sample, for cotinine
assay, and blood samples, for assays including lipids, CRP,
and ﬁbrinogen. Cholesterol concentrations were measured
using cholesterol oxidase assays on an Olympus 640 ana-
lyser (Olympus, Canter Valley, PA, USA) prior to 2010 and,
subsequently, a Roche Modular P analyser (Roche, Basel,
Switzerland). CRP concentrations were determined using
the N Latex CRP mono-immunoassay on the Behring
Nephelometer II analyser (Behring, Milan, Italy). Fibrinogen
concentrations were measured using the Organon Teknika
MDA 180 analyser (Organon, Oss, the Netherlands). Cotin-
ine was assayed using a Hewlett Packard hp5890 gas
chromatograph (Hewlett Packard, Palo Alto, CA, USA).Inclusion criteria and deﬁnitions
In this study, data from the 1998, 2003, 2008, 2009, and
2010 surveys were amalgamated as they collected consis-
tent information on cotinine, CRP, ﬁbrinogen, and lipid
concentrations. Inclusion was restricted to participants aged16 years who provided saliva and serum samples, and
were not taking nicotine replacement products. Non-
smokers were deﬁned as self-reported never or ex-smokers
who had a salivary cotinine concentration <15.0 ng/mL.
Current smokers were deﬁned as self-reported current
smokers who had a cotinine concentration 15.0 ng/mL.25
Among nonsmokers, SHS exposure was classiﬁed into low
(cotinine <0.7 ng/mL), moderate (cotinine 0.7e2.6 ng/mL),
and high (cotinine 2.7 ng/mL). Current smokers were
categorized into light (cotinine 15.0e100.0 ng/mL), mod-
erate (cotinine 100.1e300.0 ng/mL), and heavy (cotinine
>300.0 ng/mL). Body mass index (BMI) was categorized
into normal weight (<25 kg/m2), overweight (BMI 25e
30 kg/m2), and obese (30 kg/m2).26 Alcohol consumption
was based on self-report and classiﬁed as never drinker, ex-
drinker, low-risk drinker (men <28 units/week; women
<21 units/week), increasing risk drinker (men <50 units/
week; women <35 units/week), and high-risk drinker (men
50 units/week; women 35 units/week). Physically active
was deﬁned as self-report of any kind of physical activity for
at least 3 hours per week.Statistical analyses
The characteristics of nonsmokers and current smokers
were summarized using frequencies and percentages for
categorical data, medians, and interquartile ranges for
nonparametric continuous data (CRP), and mean and SD for
parametric continuous data (ﬁbrinogen and lipids). The
differences between exposure groups were assessed using
chi-square tests for categorical variables and analysis of
variance for continuous variables. Nonsmokers and current
smokers were included in the same model in order to
examine the effect of increasing cotinine concentration
across the whole spectrum from nonsmokers protected
from SHS exposure to heavy active smokers. Univariate and
multivariate median regression models were used to
examine the association between cotinine concentration
and serum CRP using nonsmokers with low SHS exposure
(cotinine <0.7 ng/mL) as the referent category. General
linear regression models were used, in the same way, to
examine the associations between cotinine concentration
and ﬁbrinogen and lipid concentrations. Three models were
developed for each assay: unadjusted; partially adjusted
(age and sex); and fully adjusted (age, sex, social class, BMI,
alcohol consumption, and physical activity). Interactions
with covariates were tested. Statistical signiﬁcance was
deﬁned as a two-sided p-value <.001 for main effects and
<.05 for interactions. All statistical analyses were under-
taken using Stata 12.0 (Stata Corporation, College Station,
TX, USA).
RESULTS
Of the 51,802 participants in the Scottish Health Surveys,
38,436 were aged 16 years. Of these, 180 were excluded
because they were taking nicotine replacement therapy
(nicotine chewing gum, patch, or nasal spray). Of the
remaining 38,256, 10,512 provided saliva and blood
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eighty-four (3.7%) were excluded because they classiﬁed
themselves as nonsmokers but had a cotinine concentration
15.0 ng/mL, 94 (0.9%) because they classiﬁed themselves
as current smokers but had a cotinine concentration
<15.0 ng/mL, and 16 (0.1%) because of missing smoking
status. The remaining 10,018 participants constituted the
study population (Fig. 1).
Of the 10,018, 7,345 (73.3%) were nonsmokers and 2,673
(26.7%) were current smokers and, of the 2,725 ex-smokers,
2,604 (95.6%) had quit smoking at least 1 year previously.
Among the nonsmokers, 2,208 (30.1%) had either moderate
or high exposure to SHS. Of the current smokers, 208
(7.8%), 980 (36.7%), and 1,485 (55.5%) were light, moder-
ate, and heavy smokers, respectively. Across the different
cotinine groups, there were differences in age, sex, social
class, BMI category, physical activity, and alcohol con-
sumption (Table 1).
CRP, ﬁbrinogen, and cholesterol concentrations and
total:HDL cholesterol ratios differed by cotinine concentra-
tion (Table 1). CRP concentration and total:HDL cholesterol
ratio increased with increasing cotinine concentration but
exhibited a step reduction between high-exposure non-
smokers and light active smokers (Table 1). Conversely, HDL
cholesterol concentration fell with increasing cotinine con-
centration but exhibited a step increase at the same point.
There was no clear pattern relating to ﬁbrinogen (Table 1).Figure 1. Flow diagram of particiThe median regression analyses suggested a dose rela-
tionship whereby CRP concentration increased with
increasing cotinine concentration among nonsmokers and
among smokers, but there was a step between high expo-
sure nonsmokers and light active smokers. In the fully
adjusted model, nonsmokers with high levels of SHS expo-
sure had CRP concentrations that were higher than non-
smokers protected from SHS exposure and were
comparable with those of light (p ¼ .709) and moderate
(p ¼ .136) active smokers (Table 2). There were statistically
signiﬁcant interactions with age (p ¼ .001) and sex
(p ¼ .002). There was evidence of a doseeresponse rela-
tionship between cotinine and CRP concentration in all
subgroups but the difference in CRP concentration between
nonsmokers protected from SHS exposure and those with
high exposure levels only reached statistical signiﬁcance in
men (p ¼ .005) and those over 60 years of age (p < .001).
In all subgroups there was no signiﬁcant difference in CRP
concentration between high-exposure nonsmokers and light
active smokers.
In the fully adjusted linear regression analysis, HDL
cholesterol concentration generally decreased with
increasing cotinine concentration. Nonsmokers with high
levels of SHS exposure had HDL cholesterol concentrations
that were lower than nonsmokers protected from SHS
exposure and were comparable with those of light active
smokers (p ¼ .931) (Table 3). There was a signiﬁcantpant inclusion and exclusion.
Table 1. Characteristics of study population by cotinine concentrations.
Cotinine (ng/mL) pa
Nonsmokers Current smokers
0e0.6
(n ¼ 5,137)
0.7e2.6
(n ¼ 1,684)
2.7e14.9
(n ¼ 524)
15.0e100.0
(n ¼ 208)
100.1e300.0
(n ¼ 980)
300.1
(n ¼ 1,485)
Age (y)
16e45 2,002 (39.0) 793 (47.1) 231 (44.1) 139 (66.8) 542 (55.3) 752 (50.6) <.001
46e59 1,422 (27.7) 444 (26.4) 114 (21.8) 43 (20.7) 233 (23.8) 466 (31.4)
60 1,713 (33.3) 447 (26.5) 179 (34.1) 26 (12.5) 205 (20.9) 267 (18.0)
Missing 0 0 0 0 0 0
Sex
Male 2,249 (43.8) 850 (50.5) 290 (55.3) 89 (42.8) 425 (43.4) 773 (52.1) <.001
Female 2,888 (56.2) 834 (49.5) 234 (44.7) 119 (57.2) 555 (56.6) 712 (47.9)
Missing 0 0 0 0 0 0
Social class
Professional 440 (8.6) 94 (5.6) 19 (3.6) 13 (6.3) 28 (2.9) 32 (2.2) <.001
Managerial technical 1,758 (34.2) 361 (21.4) 119 (22.7) 57 (27.4) 231 (23.6) 269 (18.1)
Skilled nonmanual 710 (13.8) 223 (13.2) 67 (12.8) 26 (12.5) 132 (13.5) 164 (11.0)
Skilled manual 1,308 (25.5) 592 (35.2) 175 (33.4) 61 (29.3) 290 (29.6) 501 (33.7)
Semiskilled manual 588 (11.4) 265 (15.7) 93 (17.7) 32 (15.4) 195 (19.9) 343 (23.1)
Unskilled manual 203 (4.0) 104 (6.2) 31 (5.9) 13 (6.3) 79 (8.1) 137 (9.2)
Missing 130 45 20 6 25 39
BMI (kg/m2)
<25.0 1,564 (30.4) 469 (27.9) 143 (27.3) 81 (38.9) 386 (39.4) 676 (45.5) <.001
25.0e29.9 2,008 (39.1) 647 (38.4) 198 (37.8) 79 (38.0) 312 (31.8) 461 (31.0)
30 1,174 (22.9) 430 (25.5) 145 (27.7) 36 (17.3) 198 (20.2) 231 (15.6)
Missing 391 138 38 12 84 117
Physically active
Yes 2,624 (51.1) 847 (50.3) 235 (44.8) 123 (59.1) 468 (47.8) 729 (49.1) .018
No 2,301 (44.8) 757 (45.0) 256 (50.6) 76 (36.5) 469 (47.9) 692 (46.6)
Missing 212 80 33 9 43 64
Alcohol consumption
Never drinker 322 (6.3) 75 (4.5) 33 (6.3) 4 (1.9) 31 (3.2) 47 (3.2) <.001
Ex-drinker 204 (4.0) 64 (3.8) 24 (4.6) 4 (1.9) 54 (5.5) 96 (6.5)
Low-risk drinker 4,139 (80.6) 1,321 (78.4) 371 (70.8) 145 (69.7) 695 (70.9) 1,086 (71.9)
Increasing-risk
drinker
351 (6.8) 148 (8.8) 63 (12.0) 26 (12.5) 112 (11.4) 155 (10.4)
High-risk drinker 101 (2.0) 55 (3.3) 27 (5.2) 27 (13.0) 84 (8.6) 96 (6.5)
Missing 20 21 6 2 4 5
CRP (mg/L),
median (IQR)
1.30
(0.60e3.00)
1.50
(0.60e3.50)
1.80
(0.70e4.40)
1.30
(0.50e3.65)
1.85
(0.70e4.30)
2.10
(0.90e4.60)
<.001
HDL cholesterol
(mmol/L), mean (SD)
1.52  0.42 1.47  0.39 1.43  0.39 1.50  0.43 1.42  0.40 1.37  0.38 <.001
Total:HDL cholesterol
(mean  SD)
3.94  1.33 4.00  1.30 4.32  6.24 3.73  1.23 4.14  1.69 4.48  2.33 <.001
Fibrinogen (g/L) 2.87  0.66 2.78  0.70 2.81  0.75 2.77  0.73 2.97  0.79 3.09  0.74 <.001
Note. Values given as n (%) unless otherwise stated. BMI ¼ body mass index; CRP ¼ C-reactive protein; IQR ¼ interquartile range;
HDL ¼ high-density lipoprotein.
a Chi-square test for age, sex, social class, BMI, physical activity, and alcohol consumption; KruskaleWallis test for CRP; one-way analysis of
variance test for HDL cholesterol, total:HDL cholesterol, and ﬁbrinogen.
706 L. Lu et al.interaction with sex (p < .001). The difference in HDL
cholesterol concentration between nonsmokers protected
from SHS and those with high exposure only reached sta-
tistical signiﬁcance among women (p ¼ .006) but there was
no signiﬁcant differences between HDL cholesterol con-
centrations between nonsmokers with high SHS exposure
and light active smokers among either men or women.
Total:HDL cholesterol ratios generally increased with
increasing cotinine concentration. In the fully adjusted
model, only moderate and heavy active smokers had ratiosthat were higher than nonsmokers protected from SHS
exposure. The ratios of nonsmokers with high exposure
were similar to those of light (p ¼ .405) and moderate
(p ¼ .827) active smokers (Table 3). There were signiﬁcant
interactions with both age (p < .001) and sex (p ¼ .039) but
the total:HDL cholesterol ratios generally increased with
increasing cotinine concentration in all subgroups and the
ratio was not signiﬁcantly different between nonsmokers
with high SHS exposure and light active smokers in any
subgroup. The relationship between cotinine and ﬁbrinogen
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Association Between Salivary Cotinine and Cardiovascular Biomarkers 707was less clear-cut, with only moderate and heavy active
smokers having raised concentrations (Table 3).DISCUSSION
Within both nonsmokers and active smokers, there was a
doseeresponse relationship whereby increasing exposure
to tobacco smoke was associated with higher risk con-
centrations of most cardiovascular risk biomarkers. How-
ever, there was a step change between nonsmokers and
active smokers. Compared with light and sometimes
moderately active smokers, nonsmokers exposed to high
levels of SHS had lower cotinine concentrations but com-
parable concentrations of most cardiovascular risk bio-
markers. Our ﬁndings suggest that SHS exposure carries a
disproportionately higher cardiovascular risk than would be
anticipated from extrapolation of the effects seen in active
smokers.
There is strong evidence that both active smoking and
exposure to SHS are associated with CVD.4e7 A number of
mechanisms contribute to the development of CVD,
including inﬂammation, oxidative stress, and endothelial
dysfunction.27e30 The biomarkers included in our study
relate to different pathways. CRP and ﬁbrinogen are acute-
phase proteins and markers of inﬂammation and haemo-
stasis that are strong predictors of future adverse cardio-
vascular events. Cholesterol is a major risk factor for the
development of atherosclerotic disease, with adverse ef-
fects on endothelial function and vasomotion, as well as
directly promoting atherogenesis. In contrast to total, and
especially LDL, cholesterol, the reverse cholesterol trans-
port mediated by HDL particles protects against athero-
genesis and endothelial dysfunction.31,32 Studies have
shown that active smoking is associated with increased
CRP, ﬁbrinogen, and total and LDL cholesterol concentra-
tions, and reduced total:HDL cholesterol ratios.33,34 Fewer
studies have been conducted on chronic exposure to SHS in
humans and the results are conﬂicting. In a cross-sectional
study of 995 never smokers, CRP concentrations were
0.08 mg/dL (95% CI 0.02e0.10; p ¼ .030) higher in those
exposed to SHS for more than 3 days per week compared
with those who were not exposed.22 Using data from the
Third National Health and Nutrition Examination Survey on
7,599 never smokers, Venn and Britton reported that raised
cotinine concentrations were associated with higher
ﬁbrinogen concentrations (adjusted mean difference
9.96 mg/dL, 95% CI 0.92e19.01; p ¼ .030 for cotinine
>0.215 ng/mL) but not CRP concentrations.35 Two studies
have examined the association between cotinine and CRP
across both nonsmokers and active smokers.36,37 Both
applied a cotinine concentration of 15.0 ng/mL to differ-
entiate between active and nonsmokers. Hamer et al.
studied the 13,443 people aged 35 years who partici-
pated in the English and Scottish Health Surveys conducted
between 1998 and 2004.36 Nonsmokers were categorized
into three groups, according to cotinine concentration
(<0.01, 0.06e0.70, and 0.71e14.99 ng/mL), but current
smokers were included as a single group. Also, the
Table 3. Linear regression analyses of cotinine concentration associated with high-density lipoprotein (HDL) concentration, total cholesterol concentration, and ﬁbrinogen concentration.
Cotinine (ng/mL) Unadjusted p for trend Partially adjusteda p for
trend
Fully adjustedb p for trend
Coefﬁcient (95% CI) p Coefﬁcient (95% CI) p Coefﬁcient (95% CI) p
HDL cholesterol
Nonsmokers 0e0.6c d d <.001 d d <.001 d d <.001
0.7e2.6 0.049 (0.072 to 0.027) <.001 0.027 (0.048 to 0.006) .013 0.016 (0.037 to 0.005) .134
2.7e14.9 0.092 (0.130 to 0.055) <.001 0.063 (0.099 to 0.028) <.001 0.053 (0.088 to 0.018) .003
Current smokers 15.0e100.0 0.018 (0.079 to 0.044) .568 0.005 (0.061 to 0.051) .863 0.050 (0.105 to 0.005) .076
100.1e300.0 0.102 (0.131 to 0.073) <.001 0.094 (0.121 to 0.066) <.001 0.117 (0.145 to 0.090) <.001
300.1 0.153 (0.176 to 0.129) <.001 0.127 (0.151 to 0.104) <.001 0.156 (0.178 to 0.134) <.001
Total/HDL cholesterol
Nonsmokers 0e0.6c d d <.001 d d <.001 d d <.001
0.7e2.6 0.057 (0.016 to 0.130) .124 0.046 (0.025 to 0.117) .207 0.008 (0.061 to 0.077) .810
2.7e14.9 0.378 (0.186 to 0.941) .189 0.334 (0.236 to 0.905) .251 0.297 (0.249 to 0.843) .287
Current smokers 15.0e100.0 0.207 (0.384 to 0.031) .022 0.076 (0.252 to 0.099) .395 0.055 (0.111 to 0.221) .515
100.1e300.0 0.197 (0.081e0.314) .001 0.279 (0.163e0.396) <.001 0.360 (0.247e0.472) <.001
300.1 0.536 (0.407e0.664) <.001 0.532 (0.409e0.654) <.001 0.657 (0.525e0.789) <.001
Fibrinogen
Nonsmokers 0e0.6c d d <.001 d d <.001 d d <.001
0.7e2.6 0.095 (0.136 to 0.054) <.001 0.044 (0.083 to 0.005) 0.029 0.060 (0.097 to 0.024) .001
2.7e14.9 0.065 (0.139 to 0.009) .087 0.032 (0.102 to 0.038) 0.369 0.056 (0.125 to 0.014) .116
Current smokers 15.0e100.0 0.096 (0.205 to 0.012) .081 0.018 (0.086 to 0.123) 0.734 0.265 (0.072 to 0.124) .596
100.1e300.0 0.102 (0.047e0.157) <.001 0.172 (0.118e0.225) <.001 0.171 (0.118e0.224) <.001
300.1 0.216 (0.171e0.261) <.001 0.291 (0.247e0.334) <.001 0.313 (0.270e0.356) <.001
Note. CI ¼ conﬁdence interval.
a Adjusted for age and sex.
b Partially adjusted plus social class, body mass index, physical activity, and alcohol consumption.
c Reference.
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study comprised a single group in the Hamer study. Among
nonsmokers, higher concentrations of cotinine were asso-
ciated with higher concentrations of CRP. Overall, active
smokers had higher CRP and ﬁbrinogen concentrations, and
lower HDL cholesterol concentrations, than nonsmokers,
but the investigators were not able to compare nonsmokers
exposed to high levels of SHS with light active smokers. The
adjusted hazard ratio for CHD mortality over 8 years of
follow-up was 2.00 (95% CI 1.06e3.78) for never smokers
with high SHS exposure and 1.74 (95% CI 1.24e2.46) for
current smokers.36
The British Regional Heart Study recruited individuals
aged 59 years from general practices in 24 towns. Jefferis
et al. conducted a cross-sectional study using baseline data
on 5,029 nonsmokers and light (<10 cigarettes/day) active
smokers.37 Among the nonsmokers, higher cotinine con-
centrations were associated with higher CRP (p-value for
trend <.001) and ﬁbrinogen (p-value for trend ¼ .026)
concentrations.37 Compared with nonsmokers with a co-
tinine level >0.7 ng/mL, light active smokers had higher
unadjusted mean CRP (2.29 vs. 1.78 mg/L) and ﬁbrinogen
(3.49 vs. 3.28 g/L), lower unadjusted mean HDL cholesterol
(1.49 vs. 1.53 mmol/L), and identical total cholesterol (both
6.37 mmol/L) but the investigators only calculated p-values
for a comparison between light active smokers and non-
smokers with cotinine 0.05 mg/mL.37 The risk of CHD
events over 20 years of follow-up was comparable in non-
smokers exposed to high levels of SHS (adjusted HR 1.57,
95% CI 1.08e2.28) and light active smokers (adjusted HR
1.66, 95% CI 1.04e2.68) in spite of cotinine concentrations
being nearly 30-fold higher in the latter group (mean 4.9 vs.
138 ng/mL).24
The main novelty of the present study is the direct
comparison between nonsmokers with high levels of SHS
exposure, and light and moderate active smokers using
several biomarkers. The study used data from a represen-
tative Scotland-wide survey and based SHS exposure on
salivary cotinine concentrations rather than self-report.
Salivary cotinine measurements have been shown to be
more sensitive than serum or urine cotinine concentrations
in classifying smoking status.38 Applying a cut-off of 15 ng/
mL enabled the differentiation between genuine non-
smokers exposed to high levels of SHS exposure and
smoking deceivers. Any cut-off could result in some mis-
classiﬁcations in both directions. However, the cut-off value
used complies with published guidelines and is consistent
with previous studies on this topic.25,36 Participants using
nicotine replacement therapy were excluded from the
study. No data on the use of other forms of tobacco, such as
chewing tobacco, were available, but this is used very un-
commonly in Scotland. Ex- and never smokers were com-
bined to maximize statistical power but the vast majority of
ex-smokers had not smoked for more than a year.
In the regression models, potential confounders,
including demographic, socioeconomic, and lifestyle risk
factors, were adjusted for. There were no interactions with
socioeconomic and lifestyle risk factors. To increasestatistical precision, median regression models were used to
estimate the change of median CRP value produced by one
unit change in cotinine across different levels of SHS
exposure and active smoking. In contrast to the two pre-
vious studies, all current smokers were included in the
present study and classiﬁed into three groups according to
the amount smoked in order to examine the association
between cotinine and CRP across the whole range of non-
smokers and active smokers. Nonsmokers with cotinine
concentrations >0.7 ng/mL were also split into two groups.
The overall trend in biomarkers by cotinine concentration
was examined, and the difference between nonsmokers
with high SHS exposure and light active smokers was also
speciﬁcally tested. As with the previous investigations, the
study was cross-sectional. Therefore, a temporal relation-
ship cannot be demonstrated but reverse causality is un-
likely. It is planned to corroborate the ﬁndings using
recorded linkage to incident cardiovascular events. Four
biomarkers relevant to different pathways were accessible,
but there was no access to other endothelial, inﬂammatory,
and haemostatic markers.CONCLUSIONS
The ﬁndings of this study suggest that SHS exposure is
associated with higher concentrations of cardiovascular
biomarkers than would be expected based simply on co-
tinine concentrations. This suggests that exposure to SHS
may carry a disproportionately higher cardiovascular risk
than active smoking for a given level of smoke exposure.
The ﬁndings reinforce the need to protect nonsmokers from
the harmful effects of SHS exposure.FUNDING
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